Rapport Therapeutics, Inc.
RAP-219 LAI
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for RAP-219 LAI in its lead indication are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Additionally, Rapport continues development of a long-acting injectable (LAI) formulation of RAP-219, with Phase 1 initial PK results expected in 2027.”